A
TEVA icon

AustralianSuper’s Teva Pharmaceuticals TEVA Stock Holding History

AustralianSuper’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$84.8M Sell
2,502,805
-1,053,584
-30% -$35.1M 0.37% 73
2026
Q1 		$107M Sell
3,556,389
-284,762
-7% -$9.16M 0.56% 47
2025
Q4 		$120M Sell
3,841,151
-1,120,356
-23% -$27.6M 0.56% 38
2025
Q3 		$100M Sell
4,961,507
-3,190,236
-39% -$56M 0.47% 48
2025
Q2 		$137M Sell
8,151,743
-410,479
-5% -$6.62M 0.69% 35
2025
Q1 		$132M Sell
8,562,222
-660,473
-7% -$11.8M 0.74% 34
2024
Q4 		$203M Buy
9,222,695
+1,329,319
+17% +$24.2M 0.96% 23
2024
Q3 		$142M Sell
7,893,376
-611,726
-7% -$10.7M 0.71% 45
2024
Q2 		$138M Sell
8,505,102
-1,606,968
-16% -$24.8M 0.8% 47
2024
Q1 		$141M Buy
10,112,070
+1,073,000
+12% +$13.5M 0.82% 43
2023
Q4 		$94.4M Buy
9,039,070
+1,431,671
+19% +$13.4M 0.57% 50
2023
Q3 		$77.6M Buy
7,607,399
+664,152
+10% +$6.18M 0.5% 62
2023
Q2 		$52.3M Buy
6,943,247
+4,523,700
+187% +$36.7M 0.33% 77
2023
Q1 		$21.4M Hold
2,419,547
– – 0.13% 104
2022
Q4 		$23.1M Sell
2,419,547
-437,442
-15% -$3.82M 0.15% 101
2022
Q3 		$23.1M Buy
2,856,989
+895,242
+46% +$7.92M 0.16% 94
2022
Q2 		$14.8M Sell
1,961,747
-702,819
-26% -$6.12M 0.09% 146
2022
Q1 		$25M Buy
2,664,566
+355,662
+15% +$2.97M 0.14% 107
2021
Q4 		$19.4M Sell
2,308,904
-126,851
-5% -$1.14M 0.1% 127
2021
Q3 		$23.7M Sell
2,435,755
-424,038
-15% -$3.97M 0.15% 97
2021
Q2 		$28.3M Buy
2,859,793
+887,092
+45% +$9.39M 0.2% 78
2021
Q1 		$22.8M Buy
1,972,701
+1,524,197
+340% +$17.5M 0.18% 83
2020
Q4 		$4.33M Buy
448,504
+227,592
+103% +$2.18M 0.03% 113
2020
Q3 		$1.99M Buy
+220,912
New +$2.34M 0.02% 122

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

AustralianSuper's TEVA Position: Q2 2026 in Review

AustralianSuper reduced its Teva Pharmaceuticals (TEVA) stake by 30% in Q2 2026, selling an estimated $35.1M and leaving 2,502,805 shares worth $84.8M. The position accounts for 0.37% of the portfolio, ranked #73.

AustralianSuper first reported a position in TEVA in Q3 2020 and has held it in 24 quarters since. The position peaked at $203M in Q4 2024. 672 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • AustralianSuper held 2,502,805 shares of Teva Pharmaceuticals worth $84.8M as of Q2 2026.
  • AustralianSuper sold 1,053,584 Teva Pharmaceuticals shares in Q2 2026, an estimated $35.1M.
  • Teva Pharmaceuticals made up 0.37% of AustralianSuper's portfolio in Q2 2026, its #73 holding.
  • AustralianSuper first reported a position in Teva Pharmaceuticals in Q3 2020 and has held it in 24 quarters since.
  • AustralianSuper's Teva Pharmaceuticals position peaked at $203M in Q4 2024.
  • 672 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on AustralianSuper's 13F filing for Q2 2026, filed 12 Aug 2026.